Sanofi

Today the FDA accepted the resubmission of our application for an investigational medicine for chronic spontaneous urticaria (CSU), an inflammatory skin disease driven in part by type 2 inflammation. We remain committed to bringing a new option for people suffering from this condition which causes sudden and debilitating hives and recurring itch. Learn more: http://spkl.io/6042fVJ2E Regeneron

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our #MultipleMyeloma combination therapy. If approved, this would be the first therapy in its class available in the EU, in combination with a current standard-of-care regimen, for newly diagnosed multiple myeloma patients who are transplant-ineligible. Read our press release: https://lnkd.in/dnp6T5eM

Today is #WorldDiabetesDay. 💙 We join the global community to raise awareness about this global health challenge. Empowering healthcare professionals is essential to positively impact the well-being of people with #diabetes, especially in low- and middle-income countries. Our Global Health Unit partners with International Diabetes Federation to provide online training in 40 countries which has benefited over 1,450 healthcare professionals to-date. Learn more: http://spkl.io/6044fpsRA #Sanofi #GlobalHealth #Impact #SocialImpact #DiabetesLife

How can we harness the immune system to fight type 1 #diabetes? Learn more about how Sanofi is using immunoscience to develop new treatments that stop the immune system from attacking insulin-producing cells, possibly before T1D symptoms even appear: http://spkl.io/6043fpseU

With the power of #AI, we’re discovering new ways to effectively harness the immune system and accelerate the development of new treatments for complex diseases. In a recent article published in WIRED, our visionary R&D leaders - Houman Ashrafian, Emmanuel Frenehard, and Helen Merianos - share how our approach to AI-powered immunoscience could unlock new possibilities in healthcare and deliver potentially life-changing therapies to patients faster than ever before. Read the article to learn more 👉 http://spkl.io/6049frdJZ #TransformingCare #Immunoscience

From asthma to COPD, allergies to other inflammatory conditions, the impacts of climate change on immune-driven diseases are evident. In a new Project Syndicate article, our CEO Paul Hudson discusses how global warming is increasing the prevalence and exacerbation of respiratory diseases and shares insights on strategies to help address the consequences suffered by the most vulnerable populations. Read more: http://spkl.io/6044fTlli #ClimateChange #AI

The European Commission has approved the first and only medicine for children aged 1-11 with eosinophilic esophagitis (#EoE). We’re proud to offer a treatment option that has the potential to improve the standard of care for children living with this chronic, progressive disease. Learn more about the news: https://lnkd.in/eUtjGA3b    Regeneron  

Did you know Respiratory Syncytial Virus (#RSV) can turn a family's world upside down in just a few days?  For most babies, RSV disease usually causes mild, cold-like symptoms. But in some cases, it can lead to more serious illnesses. As we mark #RSVAwarenessWeek in Europe, it's time to recognize the unseen battles that parents may face when a child contracts a severe form of RSV disease. The sleepless nights, the worry and the struggle to keep up with everyday life: it’s a tough reality. The #ResQFamily study by EFCNI - European Foundation for the Care of Newborn Infants uncovers just how families are managing these challenges. Curious about what they found? Read the full report: https://lnkd.in/e9itnGwm 

What does it take to create life-changing treatments? For Lana Vishneva, it’s all about connecting the dots. Just like creating a mosaic, Lana understands how individual pieces come together to form something meaningful ✨ 👩🔬 As one of our Product Managers, she brings our vision to life by blending research, patient insights, and team collaboration to develop treatments. Connecting with patients, listening to their stories, and witnessing the real difference her work makes is what drives her every day. Learn more about Lana's journey: http://spkl.io/6048fr65Y #WeNeverSettle #IgnitingPotential #RareDisease

Our CEO, Paul Hudson, reflects on our strong Q3, pushed forward by the momentum of our launches of innovative medicines and vaccines. Learn more about our Q3 2024 Results: http://spkl.io/6041fRCVf #SanofiResults